Patents by Inventor Undurti Narasimha Das

Undurti Narasimha Das has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180116990
    Abstract: The present application is generally directed to compositions comprising a bioactive lipid, a stabilizing agent, a solution, and ethanol. Methods associated with the preparation and use of such compositions, for example, for treating, preventing, or reversing diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity in children, or diabetic macular edema in a subject in need thereof, are also provided.
    Type: Application
    Filed: October 4, 2017
    Publication date: May 3, 2018
    Inventor: Undurti Narasimha Das
  • Patent number: 8153392
    Abstract: A method of detecting, diagnosing and prognosticating atherosclerosis by measuring the activities of ?6 and ?5 desaturases is described. It is suggested that enhancing the activities of ?6 and ?5 desaturases results in an increase in the plasma, leukocyte, platelet and endothelial cell levels of ?-linolenic, dihomo-?-linolenic, arachidonic, stearidonic, 20:4 ?-3, eicosapentaneoic and docosahexaenoic acids and PGE1 (prostaglandin E1), prostacyclin (PGI2), prostaglandin I3 (PGI3), lipoxins, resolvins, protectins, nitric oxide, and nitrolipids that prevent, arrest and reverse atherosclerosis. The invention is also directed to the delivery of proteins, peptides, lipids, lipoproteins, glycolipids, statins and troglitazones and their derivatives, and other compounds (synthetic or natural), cDNA clones and genes of ?6 and ?5 desaturases to enhance the activities of ?6 and ?5 desaturases in vivo to prevent, arrest, reverse and treat atherosclerosis.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: April 10, 2012
    Inventors: Appa Rao Allam, Undurti Narasimha Das
  • Patent number: 7666910
    Abstract: A method of stabilizing and potentiating action of molecules of known anti-angiogenic substances such as ANGIOSTATIN® or ENDOSTATIN® by using in coupling conjugation with cis-unsaturated fatty acids (c-UFAs) in the treatment of cell proliferative disorders uses c-UFAs chosen from linoleic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric acid in predetermined quantities. Preferably, the c-UFAs are in the form of polyunsaturated fatty acids (PUFAs). Uncontrolled or undesirable angiogenic activity promotes cell proliferative disorders and tumor growth, which can be inhibited by the selective use of PUFAs with anti-angiogenic substances used selectively in conjunction with predetermined anti-cancer drugs. For a non-glioma type of cell proliferation disorder, a sodium, potassium or lithium salt of a PUFA is preferred to form an admixture with an anti-angiogenic substance.
    Type: Grant
    Filed: February 27, 2002
    Date of Patent: February 23, 2010
    Inventor: Undurti Narasimha Das
  • Publication number: 20080279925
    Abstract: A method of preventing, arresting, reversing and treatment of atherosclerosis by enhancing the activities of ?6 and ?5 desaturases such that the cell, tissue, and plasma levels of various polyunsaturated fatty acids (PUFAs) and, in particular that of endothelial cells lining the blood vessels will increase. More particularly, the invention is directed to enhance the activities of ?6 and ?5 desaturases that, in turn, will lead to increased production of products of polyunsaturated fatty acids such as prostacyclin (PGI2), PGI3, lipoxins, resolvins, protecting, PGE1 (prostaglandin E1), nitric oxide, and nitrolipids such that atherosclerotic process will be prevented, arrested, reversed and this will lead to efficient arrest, regression, prevention and/or treatment of even established atherosclerosis and its associated conditions.
    Type: Application
    Filed: March 28, 2008
    Publication date: November 13, 2008
    Inventors: Appa Rao Allam, Undurti Narasimha Das
  • Publication number: 20080234197
    Abstract: A method of stabilizing and potentiating actions and administration of neurotrophins such as brain-derived neurotrophic factor (BDNF), neurotrophin-3, neurotrophin-4, and nerve growth factor and their receptors by using in coupling conjugation with polyunsaturated fatty acids (PUFAs) in the prevention and/or treatment of obesity, type 2 diabetes mellitus, metabolic syndrome X, Alzheimer's disease, depression, Parkinson's disease, and schizophrenia is described. The invention is directed to the efficacious use of various neurotrophins by using them in combination with polyunsaturated fatty acids chosen from linoleic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, cis-parinaric acid, docosapentaenoic acid and conjugated linoleic acid in predetermined quantities.
    Type: Application
    Filed: March 10, 2008
    Publication date: September 25, 2008
    Inventors: Appa Rao Allam, Undurti Narasimha Das
  • Patent number: 6617354
    Abstract: A method of stabilizing and potentiating action of molecules of known anti-angiogenic substances such as Angiostatin® or Endostatin® by using in coupling conjugation with cis-unsaturated fatty acids (c-UFAs) in the treatment of cell proliferative disorders uses c-UFAs chosen from linoleic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric acid in predetermined quantities. Preferably, the c-UFAs are in the form of polyunsaturated fatty acids (PUFAs). Uncontrolled or undesirable angiogenic activity promotes cell proliferative disorders and tumor growth, which can be inhibited by the selective use of PUFAs with anti-angiogenic substances used selectively in conjunction with predetermined anti-cancer drugs. For a non-glioma type of cell proliferation disorder, a sodium, potassium or lithium salt of a PUFA is preferred to form an admixture with an anti-angiogenic substance.
    Type: Grant
    Filed: February 27, 2002
    Date of Patent: September 9, 2003
    Inventor: Undurti Narasimha Das
  • Publication number: 20030096869
    Abstract: A method of stabilizing and potentiating action of molecules of known anti-angiogenic substances such as Angiostatin® or Endostatin® by using in coupling conjugation with cis-unsaturated fatty acids (c-UFAs) in the treatment of cell proliferative disorders uses c-UFAs chosen from linoleic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric acid in predetermined quantities. Preferably, the c-UFAs are in the form of polyunsaturated fatty acids (PUFAs). Uncontrolled or undesirable angiogenic activity promotes cell proliferative disorders and tumor growth, which can be inhibited by the selective use of PUFAs with anti-angiogenic substances used selectively in conjunction with predetermined anti-cancer drugs. For a non-glioma type of cell proliferation disorder, a sodium, potassium or lithium salt of a PUFA is preferred to form an admixture with an anti-angiogenic substance.
    Type: Application
    Filed: February 27, 2002
    Publication date: May 22, 2003
    Inventor: Undurti Narasimha Das
  • Publication number: 20020077317
    Abstract: A method of stabilizing and potentiating the actions of 2-methoxyoestradiol, statins, H2 blockers, and C-peptide of proinsulin which have modifying influence on angiogenisis and inhibiting the growth of tumor cells, peptic ulcer disease, diabete mellitus and its complications, and Alzheimer's disease as applicable by using in coupling conjugation certain polyunsaturated fatty acids (PUFAs) chosen from linoleic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, cis-parinaric acid or conjugated linoleic acid in predetermined quantities. Uncontrolled angiogenic activity and tumor growth can be inhibited by the selective use of a mixture of PUFAs with anti-angiogenic substances used selectively, and optionally in conjunction with predetermined anti-cancer drugs.
    Type: Application
    Filed: December 15, 2000
    Publication date: June 20, 2002
    Inventor: Undurti Narasimha Das
  • Patent number: 6380253
    Abstract: A method of stabilizing and potentiating action of molecules of known anti-angiogenic substances such as Angiostatin® or Endostatin® by using in coupling conjugation with cis-unsaturated fatty acids (c-UFAs) in the treatment of cell proliferative disorders uses c-UFAs chosen from linoleic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric acid in predetermined quantities. Preferably, the c-UFAs are in the form of polyunsaturated fatty acids (PUFAs). Uncontrolled or undesirable angiogenic activity promotes cell proliferative disorders and tumor growth, which can be inhibited by the selective use of PUFAs with anti-angiogenic substances used selectively in conjunction with predetermined anti-cancer drugs. For treatment of glioma, a sodium salt of a PUFA is preferred to form an admixture with an anti-angiogenic substance and a selected anti-cancer drug.
    Type: Grant
    Filed: January 5, 2000
    Date of Patent: April 30, 2002
    Assignee: EFA Sciences LLC
    Inventor: Undurti Narasimha Das